Oral Session 1-12D ALL: Clinical Trials

[OS1-12D-5] Outcomes by inotuzumab ozogamicin cycle number in patients with R/R-ALL

Yasushi Onishi¹, Davidi I. Marks², Daniel J. DeAngelo³, Elias Jabbour⁴, Anjali Advani⁵, Susan O'Brien⁶, Tao Wang⁷, Alexander Neuhof⁸, Erik Vandendries⁹, Hagop Kantarjian⁴, Wendy Stock¹⁰, Matthias Stelljes¹¹, Ryand D. Cassaday¹² (1.Tohoku University Hospital, Sendai, Japan, 2.University Hospitals Bristol, Bristol, United Kingdom, 3.Dana-Farber Cancer Institute, Boston, MA, USA, 4.University of Texas MD Anderson Cancer Center, Houston, TX, USA, 5.Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA, 6.University of California, Irvine Medical Center, Orange, CA, USA, 7.Pfizer, Inc, Groton, CT, USA, 8.Pfizer Pharma GmbH, Berlin, Germany, 9.Pfizer, Inc, Cambridge, MA, USA, 10.University of California, Irvine Medical Center, Orange, CA, USA, 11.Universitätsklinikum Munster, Germany, 12.University of Washington School of Medicine, FHCRC, Seattle, WA, USA)